OPTOGENETIC THERAPIES FOR MOVEMENT DISORDERS

• US 20150360050A1
• Filed: 06/11/2015
• Published: 12/17/2015
• Est. Priority Date: 06/11/2014
• Status: Abandoned Application

• Current Assignee: Circuit Therapeutics, Inc.
• Original Assignee: Circuit Therapeutics, Inc.
• Inventors: KAPLITT, MICHAEL, ANDERSEN, DAN
• Application Number:
  US14/737,446
• Publication Number:
  US 20150360050A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61B 2017/00057 Light
• CPC Class Codes: A61B 5/00 Measuring for diagnostic purposes radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00; Identification of persons
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61N 2005/065 Light sources therefor
• CPC Class Codes: A61N 5/062 Photodynamic therapy, i.e. excitation of an agent
• CPC Class Codes: A61N 5/0622 Optical stimulation for exciting neural tissue
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector

Abstract

One embodiment is directed to a method for controllably managing motor function in the central nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising: providing a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure, a light source configured to provide light to the light delivery element, and a controller operatively coupled to light source, wherein the targeted tissue structure is a portion of the basal ganglia of the patient; and automatically operating the controller to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.

Claims

1. A method for controllably managing motor function in the central nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising:

a. providing a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure, a light source configured to provide light to the light delivery element, and a controller operatively coupled to light source, wherein the targeted tissue structure is a portion of the basal ganglia of the patient; and

b. automatically operating the controller to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.

2. The method of claim 1, wherein the portion of the basal ganglia of the patient is selected from the group consisting of:

a subthalamic nucleus, a substantia nigra, a globus pallidus, a nucleus accumbens, and a putamen.

3. The method of claim 1, further comprising disposing an applicator to illuminate the target tissue structure, the applicator being comprised of at least a light delivery element and a sensor, wherein the sensor is configured to:

a. produce an electrical signal representative of the state of the target tissue or its environment; and

b. deliver the signal to the controller, wherein the controller is further configured to interpret the signal from the sensor and adjust at least one light source output parameter such that the signal is maintained within a desired range, wherein the light source output parameter may be chosen from the group containing of;

current, voltage, optical power, irradiance, pulse duration, pulse interval time, pulse repetition frequency, and duty cycle.

4. The method of claim 3, wherein the sensor is selected from the group consisting of:

an optical sensor, a temperature sensor, a chemical sensor, and an electrical sensor.

5. The method of claim 1, further comprising configuring the controller to drive the light source in a pulsatile fashion.

6. The method of claim 5, wherein the current pulses are of a duration within the range of 1 millisecond to 100 seconds.

7. The method of claim 5, wherein the duty cycle of the current pulses is within the range of 99% to 0.1%

8. The method of claim 1, wherein the controller is responsive to a patient input.

9. The method of claim 8, wherein the patient input triggers the delivery of current.

10. The method of claim 5, wherein the current controller is further configured to control one or more variables selected from the group consisting of:

the current amplitude, the pulse duration, the duty cycle, and the overall energy delivered.

11. The method of claim 1, wherein the light delivery element is placed about at least 60% of circumference of a nerve or nerve bundle.

12. The method of claim 1, wherein the light sensitive protein is an opsin protein.

13. The method of claim 12, wherein the opsin protein is selected from the group consisting of:

a depolarizing opsin, a hyperpolarizing opsin, a stimulatory opsin, an inhibitory opsin, a chimeric opsin, and a step-function opsin.

14. The method of claim 12, wherein the opsin protein is selected from the group consisting of:

NpHR, eNpHR 1.0, eNpHR 2.0, eNpHR 3.0, SwiChR, SwiChR 2.0, SwiChR 3.0, Mac, Mac 3.0, Arch, ArchT, Arch 3.0, ArchT 3.0, iChR, ChR2, C1V1-T, C1V1-TT, Chronos, Chrimson, ChrimsonR, CatCh, VChR1-SFO, ChR2-SFO, ChR2-SSFO, ChEF, ChIEF, Jaws, ChloC, Slow ChloC, iC1C2, iC1C2 2.0, and iC1C2 3.0.

15. The method of claim 1, wherein the light sensitive protein is delivered to the target tissue using a virus.

16. The method of claim 15, wherein the virus is selected from the group consisting of:

AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, lentivirus, and HSV.

17. The method of claim 15, wherein the virus contains a polynucleotide that encodes for the opsin protein.

18. The method of claim 17, wherein the polynucleotide encodes for a transcription promoter.

19. The method of claim 18, wherein the transcription promoter is selected from the group consisting of:

CaMKIIa, hSyn, CMV, Hb9Hb, Thy1, and Ef1a.

20. The method of claim 19, wherein the viral construct is selected from the group consisting of;

AAV1-hSyn-Arch3.0, AAV5-CamKII-Arch3.0, AAV1-hSyn-iC1C23.0, AAV5-CamKII-iC1C23.0, AAV1-hSyn-SwiChR3.0, and AAV5-CamKII-SwiChR3.0.

21. The method of claim 1, wherein the light source emits light having a wavelength that is within a wavelength range that is selected from the group consisting of:

440 nm to 490 nm, 491 nm to 540 nm, 541 nm to 600 nm, 601 nm to 650 nm, and 651 nm to 700 nm.

22. The method of claim 1, wherein the light delivery element comprises an optical fiber.